Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center
Purpose: It remains unclear whether patients with HER2-negative, low-estrogen receptor (ER-low)-positive early breast cancer (BC) benefit from Oncotype DX® (ODX) testing. Methods: We conducted a retrospective review of cases referred for ODX testing over a seven-year period from a breast biomarker t...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2024-06-01
|
| Seri Bilgileri: | Breast |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S0960977624000468 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|